AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Business & Industry
- Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
- Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
- Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
- Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
- GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses
Research & Development
- Vaccine development software shows promise in influenza effort, could help defeat coronavirus
- Researchers discover SARS-CoV-2 inhibitors
- Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
- First COVID-19 COVAX vaccine doses administered in Africa
- Assessing a compound's activity, not just its structure, could accelerate drug discovery
- Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients
- Real-world effectiveness of COVID-19 vaccine
Conferences & Events
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
Regulatory Affairs
- FDA issues Emergency Use Authorization for third COVID-19 vaccine
- FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
- FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application